Immune checkpoint inhibitors—inhibit tumor‐induced immunosuppression by blocking the interaction between PD‐1/PD‐L1, or CTLA‐4/B7 pathways to restore T‐cell antitumor immune response. This evidence concerns the gene CTLA4 and neoplasm.